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Abstract
Background and objective This study proposes a model-informed approach for therapeutic drug monitoring (TDM) of 
rifampicin to improve tuberculosis (TB) treatment.
Methods Two datasets from pulmonary TB patients were used: a pharmacokinetic study (34 patients, 373 samples), and 
TDM data (96 patients, 391 samples) collected at Radboud University Medical Center, The Netherlands. Nine suitable 
population pharmacokinetic models of rifampicin were identified in the literature and evaluated on the datasets. A model 
developed by Svensson et al. was found to be the most suitable based on graphical goodness of fit, residual diagnostics, and 
predictive performance. Prediction of individual area under the concentration–time curve from time zero to 24 h (AUC 24) 
and maximum concentration (Cmax) employing various sampling strategies was compared with a previously established 
linear regression TDM strategy, using sampling at 2, 4, and 6 h, in terms of bias and precision (mean error [ME] and root 
mean square error [RMSE]).
Results A sampling strategy using 2- and 4-h blood collection was selected to be the most suitable. The bias and precision 
of the two strategies were comparable, except that the linear regression strategy was more biased in prediction of the AUC 24  
than the model-informed approach (ME of 9.9% and 1.5%, respectively). A comparison of resulting dose advice, using pre-
dictions on a simulated dataset, showed no significant difference in sensitivity or specificity between the two methods. The 
model was successfully implemented in the InsightRX precision dosing platform.
Conclusion Blood sampling at 2 and 4 h, combined with model-based prediction, can be used instead of the currently used 
linear regression strategy, shortening the sampling by 2 h and one sampling point without performance loss while simultane-
ously offering flexibility in sampling times.
Key Points 
We propose a new model-informed therapeutic drug 
monitoring method for rifampicin.
The proposed method uses only two blood samples at 2 
and 4 h after dosing.
In contrast to linear regression-based methods, the 
proposed method allows for flexible sampling times and 
prediction of optimal dose adjustment.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 2-018-00732 -2) contains 
supplementary material, which is available to authorized users.
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1 Introduction
In 2016, the global incidence of tuberculosis (TB) was esti-
mated at 10.4 million and it remains one of the most com-
mon causes of death worldwide, with approximately 1.7 mil-
lion fatalities annually [1]. The treatment success rate for 
new and recurrent TB cases was estimated at 83% globally 
in 2015. A substantial portion of patients fail to respond 
to treatment, have a relapse of disease, or develop drug-
resistant TB [1].
There are multiple reasons for suboptimal treatment 
response, one of which is low plasma concentrations of TB 
drugs [2, 3]. Low drug exposures can result from a variety of 
reasons, e.g. malabsorption caused by HIV co-infection, dia-
betes mellitus as a concomitant disease, or other unexplained 
interindividual variability in pharmacokinetics (PK) [4–7].
Therapeutic drug monitoring (TDM) is a tool to avoid 
suboptimal treatment by measuring an individual’s drug 
exposure, comparing the result with a drug-specific tar-
get level and adjusting the patient’s dose accordingly. The 
application of TDM and its benefits in TB clinical practice 
have previously been described [2]. As it is not practically 
feasible or desirable, from a patient perspective, to sample 
intensively to obtain a full PK curve, the estimation of expo-
sure is often based on one or a few samples using a limited 
sampling strategy (LSS). The benefits of LSSs are apparent, 
including reduced inconvenience and possibly a shorter stay 
at a hospital facility for patients, as well as less labour and 
costs for the healthcare system. Traditionally, limited sam-
pling of TB drugs was aimed at ‘catching’ and estimating 
the peak plasma concentration of TB drugs in an individual 
by sampling at 2 and 6 h after dosing, as described by Alsul-
tan and Peloquin, and as applied by others [2, 5]. However, 
evolving data suggest that the total exposure (area under 
the concentration-time curve from time zero to 24 h [AUC 
24]) is more relevant to the efficacy of first-line TB drugs. 
Recently developed LSSs aim to predict the AUC 24 for TB 
drugs [2, 3, 8–10].
Rifampicin is a pillar of current first-line TB treat-
ment and is part of the World Health Organization’s List 
of Essential Medicines. Two of three identified proposed 
LSSs for rifampicin [9, 11] were established using lin-
ear regression that requires three plasma concentration 
measurements to calculate the total exposure. The LSS 
by Magis-Escurra et  al. is currently used in Radboud 
University Medical Center (Radboudumc), The Nether-
lands, and utilises three plasma samples—2, 4, and 6 h 
after dosing [9]. A linear regression formula is used to 
estimate the AUC 24 and the highest measured concentra-
tion as an approximation of the maximum concentration 
(Cmax). However, this linear regression approach has some 
limitations. For adequate predictions, the formulas demand 
use of fixed sampling time points with accurate sample 
timing. Additionally, the formulas are limited to using 
only concentration measurements from the current TDM 
occasion, ignoring patient characteristics and potential 
information from previous sampling. Furthermore, it is 
not possible to predict the change in exposure that would 
occur from a change in dosing regimen. Lastly, all cur-
rent LSSs for rifampicin [9–11] have been developed in 
populations receiving a standard dose of 10 mg/kg and 
are therefore expected to have difficulties predicting expo-
sure after higher or increased dosages, given the known 
supra-proportional increase in exposure with increasing 
doses [12].
An alternative to using a linear regression strategy 
for calculation of individual drug exposure is the model-
informed approach using a population PK model [13]. This 
approach for TDM combines population PK and individ-
ual TDM data to estimate individual PK parameters, and 
addresses all of the above limitations as it allows more 
flexible sampling, prediction of future drug concentrations, 
and incorporation of previous sampling occasions. Model-
based estimations are expected to perform better than 
limited sampling formulas and could possibly decrease 
the number of blood samples needed [14]. The aim of the 
current work was to develop a user-friendly TDM applica-
tion and LSS for the pivotal TB drug rifampicin using the 
model-informed approach.
2  Methods
We used a five-step approach to reach our objective:
• Step 1: Data collection of PK data from clinical care 
(TDM) and a previously conducted study.
• Step 2: Identification of models, i.e. identification of 
all currently known and potentially suitable rifampicin 
population PK models using a PubMed search.
• Step 3: Selection of the most suitable model, i.e. evalu-
ation of all identified rifampicin models using collected 
PK data.
• Step 4: Development of an optimal sampling strategy, i.e. 
comparison of the predictive performance of the model-
informed method with multiple potential sampling strat-
egies, and comparison of the performance of an estab-
lished linear regression formula with a three-sample LSS.
• Step 5: Numerical verification, i.e. comparison of model 
predictions and parameters between the software used 
in steps 2 and 3 and the user-friendly InsightRX dose 
individualization platform in which we incorporated our 
selected model and LSS [15].
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Figure 1 shows a schematic depiction of our approach. 
We used R version 3.2.4 [16] for data management, statis-
tics, and graphical plotting. The models were analyzed using 
the nonlinear mixed-effects modelling software NONMEM 
version 7.3 [17], executed through the Pirana workbench 
[18]. Visual predictive checks (VPCs) and stochastic simu-
lation and re-estimations (SSE) were performed using PsN 
version 4.7 [18]. Xpose4 [18] was used for graphical visu-
alization of the VPCs in R.
2.1  Data (Step 1)
We extracted routine TDM data from the electronic patient 
record system at Radboudumc. Patient data were collected 
during routine care at the Department of Respiratory Dis-
eases, Radboudumc–Dekkerswald, between 2007 and 
2017. Following the local TDM protocol, rifampicin was 
administered in a fasted state, with sampling at 2, 4, and 
6 h after dosing, at least 14 days after the start of rifampicin 
treatment [5, 9]. Some patients had several sampling occa-
sions as the TDM procedure was sometimes repeated after 
dose adjustments. A second dataset included patients from 
Radboudumc and the University Medical Center Groningen, 
The Netherlands [9]. This study recorded full PK curves, 
with samples at 1, 1.5, 2, 2.5, 3, 4, 6, 8, 12 and 24 h after 
dosing.
Quantification of rifampicin in plasma was performed 
at Radboudumc using a chromatographic assay with ultra-
violet detection, validated according to the most recent 
European Medicines Agency (EMA) guidelines for bio-
analytical method validation [19]. The method has been 
previously described in depth [20]. In short, the intra- and 
interassay coefficients of variation were < 4% over the range 
Fig. 1  Schematic representa-
tion of the study design. The 
coloured lines coming from 
the TDM and study data show 
the analyses for which these 
datasets are used. ME mean 
error, NONMEM nonlinear 
mixed effects modelling, NPDE 
normalized prediction distribu-
tion error, PK pharmacokinetic, 
RIF rifampicin, TDM therapeu-
tic drug monitoring, RMSE root 
mean square error
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of 0.28–30 mg/L. The lower limit of quantification was 
0.28 mg/L.
Observations with unknown dose or dosing time were 
excluded. Data below the limit of quantification were 
replaced by half the lower limit of quantification (the ‘M5’ 
method, as defined by Beal [21]). Fat-free mass (FFM) 
was computed as described by Janmahasatian et al. [22]. If 
weight or FFM data were missing, we used the mean of the 
variable in the corresponding dataset. All data in this study 
were pseudonymised and the institutional Ethical Review 
Board approved a waiver for the requirement to obtain 
informed consent.
2.2  Identification of Models (Step 2)
A structural PubMed search was performed to identify 
rifampicin models (the search strategy is described in Online 
Resource 1), and the references in the selected publications 
were reviewed for any additional relevant studies. The 
selection of candidate models from the identified literature 
was based on the following five criteria: the paper should 
describe (1) a population PK model (2) of rifampicin (3) 
in adult humans. Furthermore, it should be (4) an original 
publication from which (5) the model with parameter values 
could be fully re-implemented.
2.3  Selection of the Most Suitable Model (Step 3)
The TDM and PK study datasets (step 1) were used indepen-
dently to select the most suitable model. The datasets were 
used independently as they provided a better understanding 
of model performance on data of a specific nature. Selected 
models (step 2) were implemented in NONMEM for evalu-
ation with the data. If a model had a variable enzyme induc-
tion component this was fixed at maximum induction since 
we could expect a state of full induction for all patients at 
the time of sampling.
Evaluation and selection of the most suitable model was 
based on model characteristics, graphical goodness of fit, 
residual diagnostics, and predictive performance. For the 
graphical goodness of fit, we visually inspected VPCs [23, 
24], as well as individual predictions and/or time plotted 
against the measured rifampicin concentration, condition-
ally weighted residuals (CWRESs), and individual weighted 
residuals (IWRESs) [25]. These goodness-of-fit plots were 
used to evaluate the structural models and typical predictions 
of median and variability on the population level. Further 
residual diagnostic evaluation was performed using the nor-
malized prediction distribution errors (NPDEs), calculated 
using 1000 simulated datasets [23, 26]. The NPDEs are nor-
mally distributed under the null hypothesis that the model 
adequately describes the dataset. As opposed to the VPC 
for model evaluation, this allows for a statistical value to be 
computed. The normality of the NPDE was assessed using 
distribution plots and global adjusted p values. The global 
adjusted p values were based on the Wilcoxon signed rank, 
Fisher and Shapiro–Wilks tests with Bonferroni adjustment 
[26, 27].
Lastly, a priori and a posteriori root mean square errors 
(RMSEs) of the model predictions were compared to evalu-
ate bias and precision of prediction on the individual level 
with different amounts of pre-existing data. The a priori 
RMSE shows the predictive performance of the model with-
out observed concentrations and was calculated from predic-
tions based on the typical population estimates and patient 
covariate information, whereas the a posteriori RMSE shows 
the predictive performance if observed data from a first 
TDM occasion are also used to predict a future occasion. In 
this study, the a posteriori RMSE is more meaningful as it 
quantifies the predictive performance in the context of TDM. 
For the a priori and a posteriori RMSE calculation, only the 
TDM dataset was used as the study dataset did not contain 
the multiple sampling occasions per individual, needed for 
the calculations.
A single most suitable model was selected based on a 
joint assessment of the above-described evaluations. This 
model formed the basis for the model-based estimation in 
steps 4 and 5.
2.4  Development of a Sampling Strategy (Step 4)
Four potential LSSs, selected based on practical considera-
tions, were evaluated. These practical considerations were 
based on the sampling times in our data and the desirability 
to shorten the total TDM time to < 6 h to increase patient 
friendliness of the sampling strategy. The LSSs had prede-
fined fixed sampling at 2 h, 4 h, 2 and 4 h, and 2, 4 and 6 h 
after dosing. Evaluation of the fixed LSSs was performed 
using the study data and simulated data. For the latter, a 
rifampicin PK dataset of 1000 virtual individuals was simu-
lated using random sampling from individual characteristic 
distributions derived from the National Health and Nutri-
tion Examination Survey (NHANES) [28]. A more flexible 
windowed LSS, allowing sampling within a time window 
around selected time points, was also evaluated to check 
that the model could still give a good prediction when devi-
ating from the fixed sampling points. Using the previously 
described base dataset with individual characteristics, we 
generated 500 datasets in which a randomly simulated obser-
vation time point was selected within ± 30 min of each fixed 
sampling time point.
The four fixed LSSs, and subsequently the windowed 
LSS, together with model-based exposure estimation, were 
evaluated for predictive performance in comparison with 
the currently used strategy at Radboudumc developed by 
Magis-Escurra et al. [9]. In addition, the performance of the 
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model without any individual observed concentrations was 
assessed to evaluate the case without TDM. Predictive per-
formance was assessed in terms of bias and precision (mean 
error [ME] and RMSE). For the study data, the model-pre-
dicted AUC 24 on the full dataset was assumed to represent 
the true AUC 24. For the simulation data, the simultaneously 
simulated AUC 24 was the true AUC 24. The results from the 
simulation data were split into three exposure groups to 
determine predictive performance specifically for patients 
with low, middle and high exposure. The middle-exposure 
group was of special interest as we expected predictions for 
the low and high groups to be too extreme to have a signifi-
cant impact on dose advice. The first group comprised all 
individuals with a true AUC 24 from zero to half the mean 
AUC 24, as reported by Magis-Escurra et al. [9]. The second 
group ranged from half this mean to double, and the third 
group included patients having a true AUC 24 higher than 
double this mean. The RMSEs of model-based exposure 
estimation and the linear regression strategy were tested for 
significant statistical differences using the Wilcoxon signed 
rank test. The selection of the most suitable LSS was based 
on predictive performance.
Subsequently, a comparison of the resulting dose advice 
based on the predictions was performed. For this purpose, 
the previously described dataset including 1000 virtual indi-
viduals was used. This dataset was used for estimation of 
the AUC 24 applying the two exposure prediction approaches 
(linear regression vs. model-based). The dose advice, based 
on the estimated AUC 24, was compared with the dose advice 
based on the true AUC 24. The dose advice was determined 
by the guidelines used in clinical practice at Radboudumc. 
Advice to increase the dose is given when the estimated 
AUC 24 is below 30.75 h·mg/L (defined as 75% of the mean 
AUC 24 as identified by Magis-Escurra et al. [9]).
2.5  Numerical Verification (Step 5)
Implementation of the selected model in the InsightRX 
platform involved translation of the model code between 
programming languages. Similar to NONMEM [17], the 
InsightRX maximum a posteriori prediction (MAP) Bayes-
ian estimation method uses the Broyden–Fletcher–Gold-
farb–Shanno algorithm (BFGS, as implemented in the 
‘optim’ package in R) to maximize the likelihood and obtain 
individual posterior parameter estimates. InsightRX uses the 
open source library PKPDsim [29] to obtain solutions for the 
differential equation PK model. The numerical verification 
comprised of the comparison of individual parameter esti-
mates and concentration predictions between the NONMEM 
and InsightRX (R/PKPDsim) version of the model. An arbi-
trarily defined maximum allowed difference was set to 0.5%.
3  Results
3.1  Data (Step 1)
TDM data were available for 96 TB patients (391 samples), 
while the PK study provided 373 samples from 34 patients 
[9]. The characteristics of both the study and TDM data are 
Table 1  Description of utilized 
datasets
BLQ below the limit of quantification, TDM therapeutic drug monitoring
a 450 mg for patients with weight < 45 kg, and 600 mg for patients with weight > 45 kg
b Only occasions of patients taking a dose of 600 mg were included to facilitate comparison; this included 
64.7% of the observations for the TDM data and 97.1% for the study data
Characteristic TDM data Study data
Data origin Routine patient care Study by Magis-Escurra et al. [9]
Number of patients 96 34
Number of samples 391 373
Age, years [median (range)] 51.5 (17–84) 45.5 (21–83)
Males, % 72 85
Weight, kg [median (range)] 59.85 (39.5–129.1) 64.8 (43–128.8)
Dose, mg [median (range)] 600 (450–2100) 600 (450–600)a
Concentration at 2 h [median (range)]b 7.29 (0.14–29.78) 7.75 (0.14–21.41)
Concentration at 4 h [median (range)]b 5.28 (0.14–32.03) 6.31 (1.04–14.91)
Concentration at 6 h [median (range)]b 2.88 (0.59–19.72) 3.00 (0.46–7.35)
Data BLQ, % 9.2 25.5
Typical number of samples/occasions 3 10
Sampling schedule 2, 4 and 6 h after dosing 10 samples spread out between 0 
and 24 h after dosing
Sampling occasions [n (patients)] 1 (72), 2 (16), 3 (6), 4 (2) 1
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shown in Table 1. The measured plasma concentrations for a 
standard rifampicin dose of 600 mg at 2, 4, and 6 h after dos-
ing were comparable between the two datasets. Weight data 
were missing in 25% of patients in the TDM dataset, while 
FFM was missing in 26% of patients in the TDM dataset and 
6% of patients in the study dataset.
3.2  Identification of Models (Step 2)
The PubMed search resulted in 271 hits. Twelve popula-
tion PK models of rifampicin from between 1997 and 2017 
were identified [10, 30–40]. No additional relevant publica-
tions were found in the references of the selected articles. 
The characteristics of the twelve models are summarised in 
Table 2 [10, 30–42]. Three of these models were not imple-
mented for further testing as the publications either did not 
report the distribution shape of included interindividual 
variability [10] or reported it in a format not used by NON-
MEM [30, 32].
3.3  Selection of the Most Suitable Model (Step 3)
Based on assessment of the VPCs (shown in Online 
Resource 2), the best-performing models were those by 
Savic et al. [37], Milán Segovia et al. [34] and Svensson 
et al. [40]. Observed concentrations plotted against the 
individual prediction showed good predictive performance 
from the models by Smythe et al. [33], Chirehwa et al. 
[39] and Svensson et al. (data not shown, except for the 
models by Chirehwa et al. and Svensson et al. as reported 
in the online supplementary material). Based on the indi-
vidual plots of the observed concentration versus time, 
the models by Chirehwa et al. and Svensson et al. had 
the best individual prediction (data not shown). Based on 
these assessments, we narrowed the candidates for the 
Table 2  Summary of identified population PK models for RIF
CL clearance, F bioavailability, FDC fixed-dose combination, FFM fat-free mass, HIV human immunodeficiency virus, MTT mean transit time, 
NFM normal fat mass, PK pharmacokinetics, RIF rifampicin, SDF single-dose formula, TB tuberculosis, V volume of distribution, WT weight
a Excluded because the publication did not report the distributions of the included interindividual variability in a format usable by NONMEM
b Excluded because the publication did not report the distributions of the included interindividual variability
Authors (year) Covariate–parameter rela-
tionships
Population, country of 
origin (n)
Model structure Selected 
for evalua-
tion
References
Peloquin et al. (1997) – Healthy adult males, USA 
(24)
One-compartment Noa [30]
Wilkins et al. (2008) FDC/SDF-CL, FDC/SDF-
MTT
Pulmonary TB patients, 
South Africa (261)
One-compartment, transit 
compartment
Yes [31]
Goutelle et al. (2009) – AIDS patients (20) and 
healthy volunteers (20), 
USA [41] (40)
Three-compartment Noa [32]
Smythe et al. (2012) NFM-CL, NFM-V
HIV-V
Pulmonary TB patients, 
Africa (174)
One-compartment, transit 
compartment, auto-induc-
tion
Yes [33]
Milán-Segovia et al. (2013) Sex-CL, Sex-V TB patients, Mexico (171) One-compartment, lag time Yes [34]
Seng et al. (2015) – Healthy adults, Asia (34) One-compartment, transit 
compartment
Yes [35]
Sturkenboom et al. (2015) – TB patients, The Nether-
lands (55)
One-compartment Nob [10]
Jing et al. (2015) – Pulmonary TB patients, 
China (54)
One-compartment Yes [36]
Savic et al. (2015) WT-CL, WT-V TB meningitis patients, 
Indonesia (53)
Two-compartment Yes [37]
Schipani et al. (2016) Age-F, Age-CL,
WT-CL, WT-V
TB patients, adults (115) 
and children (50), Malawi 
(165)
One-compartment Yes [38]
Chirehwa et al. (2016) FFM-CL, FFM-V HIV-infected TB patients, 
South Africa [42] (61)
One- compartment, transit 
compartment, auto-induc-
tion
Yes [39]
Svensson et al. (2017) FFM-CL, FFM-V Pulmonary TB patients, 
South Africa (83)
One-compartment, transit 
compartment, auto-induc-
tion
Yes [40]
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most suitable model down to those by Chirehwa et al. and 
Svensson et al.
Plots of CWRES and IWRES indicated that the model by 
Svensson et al. was preferable over the model by Chirehwa 
et al. (see Online Resource 3). The CWRES plotted against 
time showed a trend for both models, however the model 
by Svensson et al. performed better in the range of 2–12 h, 
in which most of the important PK of rifampicin are situ-
ated. The model by Svensson et al. performed better than the 
model by Chirehwa et al. on all IWRES plots.
Only the NPDEs from the model by Svensson et al. were 
shown to not differ from the normal distribution on the study 
data (global-adjusted p value of 0.07). No NPDEs were nor-
mally distributed for the models on the TDM data; however, 
the NPDEs from the model by Svensson et al. showed the 
least deviation from normality on the TDM dataset com-
pared with the other models (data not shown).
The a priori and a posteriori RMSEs are shown in Fig. 2, 
and were calculated based on the PK data of patients from 
the TDM data who had a second TDM occasion (n =16). The 
least well-performing models were the models by Schipani 
et al. [38] and Wilkins et al. [31]. The model by Chirehwa 
et al. performed best, with the model by Svensson et al. a 
close second.
Overall, the models by Chirehwa et al. [39] and Sven-
sson et  al. [40] were found to have the best predictive 
performance, with minimal differences between the two. 
Ultimately, the model developed by Svensson et al. was 
considered the most suitable for TDM purposes as it was 
based on rifampicin doses from 10 to 40 mg/kg, instead 
of 10 mg/kg only in the model by Chirehwa et al., which 
may be important for TDM in the near future as high-dose 
rifampicin treatment may become more common [43]. The 
model by Svensson et al. is a one-compartment model with 
absorption through transit compartments, and includes an 
enzyme turnover model, concentration-dependent clearance, 
and dose-dependent bioavailability [40]. Figure 3 shows the 
VPCs of the model by Svensson et al. on our data.
3.4  Development of a Sampling Strategy (Step 4)
The predictive performance (ME and RMSE) using the study 
data of the four proposed model-informed LSSs, as well as 
the model without sampling, were compared with the linear 
regression strategy in Table 3. This comparison showed that 
every LSS performed better than model prediction without 
sampling. The fixed one-sample, model-informed LSSs 
performed worse than the currently used linear regression 
strategy. The 2- and 4-h and 2-, 4- and 6-h model-informed 
Fig. 2  A priori and a posteriori RMSEs of the population pharmacokinetic models of rifampicin (calculated on patients who had at least two 
TDM occasions; n =16). RMSE root mean square errors
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LSSs were less biased and as precise as the currently used 
linear regression strategy.
The 2- and 4-h and 2-, 4- and 6-h model-informed LSSs 
were also compared with the linear regression strategy 
regarding predictive performance using simulated data. This 
comparison is shown in Table 4 and is grouped according 
to true exposure. In the low- and middle-exposure groups, 
the model-informed approach had similar performance 
compared with the linear regression strategy. In the high-
exposure group, the linear regression strategy generally 
outperformed the model-informed approach on predictive 
performance, except for the RMSE of Cmax prediction.
The model-informed LSS using 2- and 4-h sampling was 
selected as the most suitable for model-informed TDM, 
based on the fact that the predictive performance was sat-
isfactory, and on the practical benefit of having only two 
sampling points instead of three. A windowed variant of 
this LSS was evaluated (its predictive performance is also 
shown in Table 4). Overall, the performance was comparable 
with its fixed sampling counterpart, demonstrating that the 
model also generates good predictions with flexible sam-
pling points or deviations in sampling times.
A comparison of the resulting dose advice from predic-
tions on the simulated data between the fixed 2- and 4-h 
model-informed LSS and the linear regression strategy is 
shown in Table 5. No statistically significant difference in 
sensitivity and specificity was found between the model-
informed approach and the linear regression strategy.
Fig. 3  Visual predictive checks of the model by Svensson et al. [40] 
on (a) the TDM data, and (b) the study data. The red lines represent 
the mean of the observed concentrations and the blue lines represent 
the 5th or 95th quartiles. The red and blue shaded areas represent 
the 95% confidence interval of the mean, and 5th or 95th quartiles, 
respectively, of the simulated concentrations. TDM therapeutic drug 
monitoring
Table 3  Predictive performance 
of the LSSs on the study data
Both the ME and RMSE are depicted as a percentage of the mean of the corresponding PK parameter in 
the study data, as reported by Magis-Escurra et  al. [9]. The difference in RMSE observed with the cur-
rently used linear regression strategy and each of the model-based strategies was tested using the Wilcoxon 
signed rank test
AUC 24 area under the 24-h time curve, Cmax maximum concentration, LSS limited sampling strategy, ME 
mean error, PK pharmacokinetic, RMSE root mean square error
*p < 0.05, **p < 0.01
Method and sampling strategy AUC 24 Cmax
ME (%) RMSE (%) ME (%) RMSE (%)
Linear regression, fixed 2-, 4-, and 6-h samples 9.9 16.9 1.9 14.4
Model, no sampling 41.5 55.0** 28.9 39.7**
Model, fixed 2-h sample − 14.1 38.4* − 6.2 22.8*
Model, fixed 4-h sample 5.1 23.2 − 0.3 29.9**
Model, fixed 2- and 4-h samples 1.5 17.7 − 1.6 18.7
Model, fixed 2-, 4-, and 6-h samples − 0.1 15.1 − 1.7 18.9
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3.5  Numerical Verification (Step 5)
Comparison of individual parameter estimates for the model 
by Svensson et al. obtained with the InsightRX MAP estima-
tion engine versus parameters obtained using the same model 
implemented in NONMEM deviated only minimally (< 0.5%), 
as shown in Online Resource 4. Consequently, concentration 
predictions from the InsightRX PK simulation engine (based 
on the obtained individual estimates) versus predictions from 
NONMEM showed a negligible difference (< 10−3 mg/L) [see 
Online Resource 5].
4  Discussion
With this work, we have shown that model-informed preci-
sion dosing of rifampicin is feasible and offers benefits over 
the standard limited-sampling approach. After following a 
careful procedure for model evaluation focusing on exposure 
prediction, we selected the population PK model by Sven-
sson et al. as the best model suitable for TDM of rifampicin 
for our population. We developed and validated a sampling 
strategy with only two flexible time points to estimate indi-
vidual exposures.
There are multiple benefits to using the model-informed 
approach instead of a linear regression approach for the pur-
pose of TDM. (1) It is flexible in handling sampling time 
deviations. Where a linear regression strategy can only use 
fixed sampling times, a model is far more flexible in using 
different sampling times. In current clinical practice, real 
sampling times often deviate from the scheduled times. 
These deviations decrease predictive performance when 
using a linear regression approach, but not as much with a 
model-informed approach. (2) Individual characteristics and 
dose history are regarded, which provides more informed 
individual predictions. (3) Additionally, previous pharma-
cokinetic observations may also be taken into account for 
predictions. (4) A model-informed approach can predict 
future exposure resulting from a proposed adjusted dose. 
Table 4  Predictive performance 
of the LSS on simulated data
Both the ME and RMSE are depicted as a percentage of the mean of the corresponding PK parameter in 
the study data, as reported by Magis-Escurra et  al. [9]. The difference in RMSE observed with the cur-
rently used linear regression strategy and each of the model-based strategies was tested using the Wilcoxon 
signed rank test
AUC 24 area under the 24-h time curve, Cmax maximum concentration, LSS limited sampling strategy, ME 
mean error, PK pharmacokinetic, RMSE root mean square error
*p < 0.05, **p < 0.01
Method and sampling strategy AUC 24 Cmax
ME (%) RMSE (%) ME (%) RMSE (%)
True AUC 24 < 15.4 h mg/L (n = 40)
 Linear formula, fixed 2-, 4- and 6-h samples − 1.5 6.2 − 4.8 13.6
 Model, fixed 2- and 4-h samples 3.4 8.1 5.8 14.1
 Model, window with a half hour range around 2 and 4 h 4.0 8.3 6.3 16.7**
 Model, fixed 2-, 4- and 6-h samples 3.7 8.1 5.8 14.1
True AUC 24 15.4–61.5 h mg/L (n = 807)
 Linear formula, fixed 2-, 4- and 6-h samples 1.5 19.8 − 11.2 38.0
 Model, fixed 2- and 4-h samples − 5.4 19.4 − 3.7 31.5**
 Model, window with a half hour range around 2 and 4 h − 5.6 19.6** − 3.5 32.3**
 Model, fixed 2-, 4- and 6-h samples − 3.7 15.8** − 3.6 31.6**
True AUC 24 > 61.5 h mg/L (n = 153)
 Linear formula, fixed 2-, 4- and 6-h samples − 4.0 34.8 − 1.9 33.2
 Model, fixed 2- and 4-h samples − 45.9 57.8** − 13.4 26.6**
 Model, window with a half hour range around 2 and 4 h − 48.8 60.3** − 14.4 27.0**
 Model, fixed 2-, 4- and 6-h samples − 30.5 42.5** − 11.4 25.9**
Table 5  Comparison of dose advice performance
The sensitivity (true positive rate/how often the model suggests a 
dose increase when it should) and the specificity (true negative rate/
how often the model does not suggest a dose increase when it should 
not) for the most suitable model-based sampling strategy and the lin-
ear regression strategy on a simulated dataset including 1000 patients
Model, 2- and 4-h 
sampling
Regression, 2-, 4- 
and 6-h sampling
Sensitivity [% (95% CI)] 79.5 (74.2–84.0) 87.1 (82.4–90.6)
Specificity [% (95% CI)] 88.1 (85.5–90.3) 91.0 (88.6–92.9)
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(5) Specific to the model by Svensson et al. [40] is that it 
can handle the nonlinear PK of rifampicin, which is ben-
eficial for exposure prediction of changes in dose, espe-
cially as patients are increasingly prescribed higher doses 
of rifampicin [12, 40, 43–45]. (6) Furthermore, the model 
is also able to capture variable absorption, theoretically giv-
ing it an edge over the linear regression strategy in case of 
delayed absorption.
Although the model-informed approach has many advan-
tages, a downside could be its complexity; it requires sophis-
ticated software, understanding of the technology and a 
significant time investment [10, 46]. Implementation of the 
model in a user-friendly interface, such as the InsightRX 
platform, is expected to greatly improve the ease of use in 
clinical practice and facilitate its implementation in clinical 
practice.
Although the selected population pharmacokinetic 
model could be used to investigate optimal dosing regimens 
in silico for the population, this was beyond the scope of 
our study. Our aim was to develop and validate a model-
informed precision dosing strategy, independent of starting 
dose, which can also be further implemented in other popu-
lations and strategies. We point out that implementation of 
our strategy in other populations or settings should not be 
employed without ‘fit-for-purpose qualification’ [48]. How-
ever, as the selected model by Svensson et al. [40] was based 
on a South African population, and the datasets for develop-
ment and validation were from a Dutch clinical setting, this 
may indicate that the selected model may also perform well 
in other settings.
A secondary contribution of this work was to provide 
a blueprint for how to evaluate and select population PK 
models to be used in TDM procedures. In this regard, some 
points should be mentioned. For the prediction performance 
comparison using the study data, it could be argued that a 
noncompartmental method for estimation of the true AUC 
24 could be more fitting than model estimation on the full 
dataset. However, it is thought that estimation by the model 
can be a better approximation of the truth as it is able to take 
measurement errors into account, which is why the model-
predicted AUC 24 was used [47]. In addition, since part of the 
data utilised in our evaluation of the LSS was initially used 
in the development of the linear regression strategy, it may 
be that the predictive performance of the linear regression 
strategy is inflated. The fact that these data have no sampling 
time deviations probably adds to the performance overesti-
mation of the linear regression strategy for clinical practice. 
The probable overestimation of performance for the linear 
regression strategy further strengthens the notion that the 
proposed model-informed approach would outperform the 
linear regression strategy in clinical practice.
Some limitations specific to this study should be dis-
cussed. One potential shortcoming is that a more efficient 
LSS could have been developed by means of optimal design 
experiments. Nonetheless, we were able to validate the pro-
posed strategy on already existing data with predefined sam-
pling times. Another drawback is that the model by Chirehwa 
et al. [39] had similar predictive performance results as the 
model by Svensson et al. [40], but only the latter was used to 
develop the LSS. The model by Svensson et al. was regarded 
as being more representative for high-dose rifampicin as it 
was based on data with a wide dose range of 10–40 mg/kg, 
instead of only 10 mg/kg. Furthermore, the linear regression 
strategy from Magis-Escurra et al., to which we compare 
our model-informed approach, was developed to be optimal 
for five TB drugs, including rifampicin [9]. While the final 
linear regression strategy from that study was not the most 
optimal for rifampicin, all feasible suggested alternatives 
included a late sampling time at 6 h after dosing, which was 
avoided in the development of our LSS in order to reduce the 
time spent in the clinic by the patient. Lastly, the proposed 
model-informed strategy is seemingly outperformed by the 
linear regression strategy in individuals in the high-exposure 
group. This effect is inherent to the model-informed method 
as predictions are weighted towards the typical individual by 
the prior information. The individuals in the high-exposure 
group are extremes, with a relatively high exposure for this 
dosing schedule and population; therefore, their model-
based predictions will be weighted down toward the typi-
cal individual. In practice, the dosing platform would give 
warnings when the fit is poor and suggest different courses 
of action for the clinician to take, e.g. to downweigh the 
model priors to rely more on the observed data and/or to 
gather more data on the patient to confirm or disprove the 
extreme values [48]. However, as predictions for individuals 
with extreme exposure are still well-removed from the dose-
adjustment target, misprediction in these individuals will 
not affect dose-adjustment decisions. The clinical relevance 
of these mispredictions are therefore of negligible clinical 
relevance.
5  Conclusions
Our model-informed TDM strategy effectively shortens the 
sampling time by 2 h and removes one sampling point with-
out performance loss compared with the sampling currently 
implemented in our hospital. Furthermore, it is more flex-
ible, provides a more informed prediction, and can account 
for variable absorption and the nonlinear PK of rifampicin 
compared with all commonly used linear regression strate-
gies. TDM can improve the response to TB treatment, and, 
in this study, we show that model-informed methods can 
simplify TDM, reducing its implementation hurdles, which 
may translate to benefit in TB patients.
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